Encoded Therapeutics closed a $275 million Series F round led by GV and an undisclosed healthcare investor, funding its Dravet syndrome program and efforts to scale internal genetic-medicine manufacturing. The precision genetic medicine biotech said the financing will support both clinical execution and manufacturing capacity. The move highlights investor appetite for franchise-building in severe pediatric epilepsy, where durable efficacy and scalable production remain key bottlenecks. It also signals confidence in Encoded’s platform as the company prepares additional milestones tied to its lead asset. For the broader market, the round underscores that large-scale manufacturing infrastructure is increasingly viewed as a competitive differentiator in gene and precision therapies, not just an operational detail.